Role of Helicobacter Pylori and Its Toxins in Lung and Digestive System Diseases
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00366509 |
Recruitment Status
:
Completed
First Posted
: August 21, 2006
Last Update Posted
: March 29, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
This study will examine bacteria and toxins in the mouth, lung and digestive system that may be the cause of various diseases or symptoms. H. pylori is a bacterium that produces various toxins that may contribute to lung problems. This study will examine specimens collected from the mouth, teeth, lung, digestive tract and blood to measure H. pylori and its toxins and their effects on cells.
People 18 years of age and older with or without gastrointestinal disease may be eligible for this study. These include people without a history of lung disease as well as patients with any of the following: lymphangioleiomyomatosis, asthma, sarcoidosis, other chronic or genetic lung disease (e.g., chronic obstructive pulmonary disease, cystic fibrosis or eosinophilic granuloma).
Participants may undergo the following tests:
- Blood and urine tests, chest x-ray.
- Measurement of arterial blood gases: A small needle is placed in an artery in the forearm to collect arterial blood.
- Lung function tests: Subjects breathe deeply and occasionally hold their breath. They may also receive a medication that expands the airways.
- Fiberoptic bronchoscopy with lavage and bronchial brushing: The subject's mouth and throat are numbed with lidocaine; a sedative may be given for comfort. A thin flexible tube called a bronchoscope is advanced through the nose or mouth into the lung airways to examine the airways. Saline (salt water) is then injected through the bronchoscope into the air passage and then removed by gentle suction. Next, a small brush is passed through the bronchoscope and an area of the airway is brushed to collect some cells for examination.
- Mouth rinsing or teeth brushing to collect cells.
- Endoscopy: A small needle and catheter (thin plastic tube) are placed into an arm vein to administer fluids and medications through the vein. A sedative may be given. The throat is numbed with lidocaine and a thin flexible tube called an endoscope is inserted through the mouth and down the esophagus into the stomach and upper part of the small intestine to examine those areas.
Condition or disease |
---|
Pulmonary Disease Oropharyngeal Disease Lymphangioleiomyomatosis Pulmonary Fibrosis Asthma Sarcoidosis |
Study Type : | Observational |
Actual Enrollment : | 157 participants |
Official Title: | Role of Helicobacter Pylori and Its Toxins in Pulmonary and Oropharyngeal Disease |
Study Start Date : | August 8, 2006 |


Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
- INCLUSION CRITERIA:
Individuals who are 18 years of age or older with or without a history of gastrointestinal disease and with any of the following:
- lymphangioleiomyomatosis, or
- asthma, or
- sarcoidosis, or
- pulmonary fibrosis, or
- other chronic or genetic lung diseases (e.g., chronic obstructive pulmonary disease, eosinophilic granuloma, cystic fibrosis, Wegener's granulomatosis, chronic bronchitis), or
- research volunteers without a history of lung disease.
EXCLUSION CRITERIA:
Individuals with any of the following:
- uncontrolled ischemic heart disease, or
- uncorrectable bleeding diathesis, or
- pregnancy or lactation, or
- inability to give informed consent, or
- risk factors for endocarditis (e.g., prosthetic cardiac valve, previous bacterial endocarditis, surgically constructed systemic pulmonary shunts or conduits, complex cyanotic congenital heart disease [e.g., single ventricle, transposition of great arteries, tetralogy of Fallot])

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00366509
United States, Maryland | |
National Institutes of Health Clinical Center, 9000 Rockville Pike | |
Bethesda, Maryland, United States, 20892 |
Principal Investigator: | Joel Moss, M.D. | National Heart, Lung, and Blood Institute (NHLBI) |
Additional Information:
Publications:
Responsible Party: | National Heart, Lung, and Blood Institute (NHLBI) |
ClinicalTrials.gov Identifier: | NCT00366509 History of Changes |
Other Study ID Numbers: |
060222 06-H-0222 |
First Posted: | August 21, 2006 Key Record Dates |
Last Update Posted: | March 29, 2018 |
Last Verified: | October 16, 2017 |
Keywords provided by National Institutes of Health Clinical Center (CC) ( National Heart, Lung, and Blood Institute (NHLBI) ):
Vac A Toxin Lung Bronchoscopy Endoscopy Cytotoxin Pulmonary Disease |
Lung Disease Genetic Disease Oropharyngeal Disease Pulmonary Fibrosis Asthma |
Additional relevant MeSH terms:
Lung Diseases Fibrosis Pulmonary Fibrosis Sarcoidosis Digestive System Diseases Lymphangioleiomyomatosis Respiratory Tract Diseases Pathologic Processes Lymphoproliferative Disorders |
Lymphatic Diseases Lymphangiomyoma Lymphatic Vessel Tumors Neoplasms by Histologic Type Neoplasms Perivascular Epithelioid Cell Neoplasms Neoplasms, Connective and Soft Tissue Immunoproliferative Disorders Immune System Diseases |